{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:04:58Z","timestamp":1786460698896,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstact<\/jats:title>\n                  <jats:p>Metformin, a first-line anti-diabetic agent, exhibits broad-spectrum antitumor properties, though its underlying immunomodulatory mechanisms remain incompletely characterized. Here, we demonstrate that metformin significantly upregulates BTN3A1 and BTN2A1 expression on esophageal cancer cells in an AMPK-dependent manner, thereby sensitizing them to V\u03b39V\u03b42 T cell-mediated cytotoxicity. This molecular priming enhanced tumor immunogenicity, leading to synergistic tumor cell killing in vitro and potent suppression of tumor growth in xenograft models. Mechanistically, metformin-induced BTN3A1\/BTN2A1 upregulation promoted V\u03b39V\u03b42 T cell activation, and Granzyme B-mediated apoptosis in tumor tissues. The combination therapy demonstrated excellent tolerability without observable systemic toxicity. Moreover, Integrating GEPIA3 database and clinical specimen analyses, we find that BTN3A1 and BTN2A1 are highly but heterogeneously expressed in esophageal cancer tissues, and that metformin\u2011mediated upregulation may restore sensitivity to V\u03b39V\u03b42 T cell immunotherapy particularly in patients with low baseline expression\u2014uncovering a novel immunomodulatory function of metformin that provides a compelling rationale for its repurposing as a combinatorial agent against immunologically cold tumors such as esophageal carcinoma.<\/jats:p>","DOI":"10.1038\/s41419-026-08924-6","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:54:56Z","timestamp":1780710896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin sensitizes esophageal squamous cell carcinoma to V\u03b39V\u03b42 T cell-mediated cytotoxicity by upregulating BTN3A1 and BTN2A1"],"prefix":"10.1038","volume":"17","author":[{"given":"Zishan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piaoyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-8777","authenticated-orcid":false,"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-0991","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2860-8320","authenticated-orcid":false,"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"8924_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cac2.12645","volume":"45","author":"W Jiang","year":"2025","unstructured":"Jiang W, Zhang B, Xu J, Xue L, Wang L. Current status and perspectives of esophageal cancer: a comprehensive review. Cancer Commun (Lond). 2025;45:281\u2013331.","journal-title":"Cancer Commun (Lond)"},{"key":"8924_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649\u2013658.e2.","journal-title":"Gastroenterology"},{"key":"8924_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.14309\/ajg.0000000000002629","volume":"119","author":"H Jiang","year":"2024","unstructured":"Jiang H, Chen R, Li Y, Hao C, Song G, Hua Z, et al. Performance of prediction models for esophageal squamous cell carcinoma in general population: A systematic review and external validation study. Am J Gastroenterol. 2024;119:814\u201322.","journal-title":"Am J Gastroenterol"},{"key":"8924_CR4","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.gie.2024.07.013","volume":"100","author":"H Jiang","year":"2024","unstructured":"Jiang H, Tian B, Gao Y, Bian Y, Yu C, Xu J, et al. Risk and pathologic factors of recurrence after endoscopic resection for superficial esophageal squamous cell carcinoma: a systematic review and meta-analysis. Gastrointest Endosc. 2024;100:1006\u20131019.e10.","journal-title":"Gastrointest Endosc"},{"key":"8924_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO Guideline. J Clin Oncol. 2023;41:1470\u201391.","journal-title":"J Clin Oncol"},{"key":"8924_CR6","doi-asserted-by":"publisher","first-page":"e012468","DOI":"10.1136\/jitc-2025-012468","volume":"13","author":"J Fu","year":"2025","unstructured":"Fu J, Huang X, Fang M, Feng X, Zhang X-Y, Xie X, et al. Artificial intelligence in medical imaging empowers precision neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. J Immunother Cancer. 2025;13:e012468.","journal-title":"J Immunother Cancer"},{"key":"8924_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70023","volume":"331","author":"F Mohammed","year":"2025","unstructured":"Mohammed F, Willcox CR, Willcox BE. A brief molecular history of V\u03b39V\u03b42 TCR-mediated phosphoantigen sensing. Immunol Rev. 2025;331:e70023.","journal-title":"Immunol Rev"},{"key":"8924_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.immuni.2025.06.009","volume":"58","author":"JP Loureiro","year":"2025","unstructured":"Loureiro JP, De Libero G. The Three Graces of T cell receptor V\u03b39V\u03b42 chain activation. Immunity. 2025;58:1615\u20137.","journal-title":"Immunity"},{"key":"8924_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41586-023-06482-x","volume":"621","author":"MR Mamedov","year":"2023","unstructured":"Mamedov MR, Vedova S, Freimer JW, Sahu AD, Ramesh A, Arce MM, et al. CRISPR screens decode cancer cell pathways that trigger \u03b3\u03b4 T cell detection. Nature. 2023;621:188\u201395.","journal-title":"Nature"},{"key":"8924_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","volume":"621","author":"L Yuan","year":"2023","unstructured":"Yuan L, Ma X, Yang Y, Qu Y, Li X, Zhu X, et al. Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells. Nature. 2023;621:840\u20138.","journal-title":"Nature"},{"key":"8924_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116387","volume":"44","author":"E Billon","year":"2025","unstructured":"Billon E, Imbert C, Bruyat D, Grassi P, Robert L, Fernez T, et al. BTN2A1 acquisition through trogocytosis enhances V\u03b39V\u03b42 T cell cytotoxicity against autologous and cancer cells. Cell Rep. 2025;44:116387.","journal-title":"Cell Rep"},{"key":"8924_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba9010","volume":"6","author":"C Harly","year":"2021","unstructured":"Harly C, Joyce SP, Domblides C, Bachelet T, Pitard V, Mannat C, et al. Human \u03b3\u03b4 T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci Immunol. 2021;6:eaba9010.","journal-title":"Sci Immunol"},{"key":"8924_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","volume":"7","author":"M Alnaggar","year":"2019","unstructured":"Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, et al. Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 2019;7:36.","journal-title":"J Immunother Cancer"},{"key":"8924_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","volume":"5","author":"M Lin","year":"2020","unstructured":"Lin M, Zhang X, Liang S, Luo H, Alnaggar M, Liu A, et al. Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5:215.","journal-title":"Signal Transduct Target Ther"},{"key":"8924_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18:427\u201339.","journal-title":"Cell Mol Immunol"},{"key":"8924_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756495","volume":"12","author":"J Liang","year":"2021","unstructured":"Liang J, Fu L, Li M, Chen Y, Wang Y, Lin Y, et al. Allogeneic V\u03b39V\u03b42 T-cell therapy promotes pulmonary lesion repair: an open-label, single-arm pilot study in patients with multidrug-resistant tuberculosis. Front Immunol. 2021;12:756495.","journal-title":"Front Immunol"},{"key":"8924_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado S, Blanco-Dom\u00ednguez R, Silva-Santos B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20:178\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"8924_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618393","volume":"16","author":"A Laub","year":"2025","unstructured":"Laub A, Rodrigues de Almeida N, Huang S. Unconventional T cells in anti-cancer immunity. Front Immunol. 2025;16:1618393.","journal-title":"Front Immunol"},{"key":"8924_CR19","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.immuni.2025.04.012","volume":"58","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Gao W, Zheng J, Bai Y, Tian X, Huang T, et al. Phosphoantigen-induced inside-out stabilization of butyrophilin receptor complexes drives dimerization-dependent \u03b3\u03b4 TCR activation. Immunity. 2025;58:1646\u20131659.e5.","journal-title":"Immunity"},{"key":"8924_CR20","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.immuni.2025.05.011","volume":"58","author":"M Zhang","year":"2025","unstructured":"Zhang M, Wang Y, Cai N, Qu Y, Ma X, Xue J, et al. Structures of butyrophilin multimers reveal a plier-like mechanism for V\u03b39V\u03b42 T cell receptor activation. Immunity. 2025;58:1660\u20131669.e7.","journal-title":"Immunity"},{"key":"8924_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad043","volume":"7","author":"Q-L Wang","year":"2023","unstructured":"Wang Q-L, Santoni G, Lagergren J. Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study. JNCI Cancer Spectr. 2023;7:pkad043.","journal-title":"JNCI Cancer Spectr"},{"key":"8924_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.14309\/ajg.0000000000000478","volume":"115","author":"Q-L Wang","year":"2020","unstructured":"Wang Q-L, Santoni G, Ness-Jensen E, Lagergren J, Xie S-H. Association between metformin use and risk of esophageal squamous cell carcinoma in a population-based cohort study. Am J Gastroenterol. 2020;115:73\u201378.","journal-title":"Am J Gastroenterol"},{"key":"8924_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.59","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5:e1088.","journal-title":"Cell Death Dis"},{"key":"8924_CR24","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3892\/ijo.2016.3676","volume":"49","author":"A Nakayama","year":"2016","unstructured":"Nakayama A, Ninomiya I, Harada S, Tsukada T, Okamoto K, Nakanuma S, et al. Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. Int J Oncol. 2016;49:1890\u20138.","journal-title":"Int J Oncol"},{"key":"8924_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","volume":"16","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zhang C, Najafi M. Targeting of the tumor immune microenvironment by metformin. J Cell Commun Signal. 2022;16:333\u201348.","journal-title":"J Cell Commun Signal"},{"key":"8924_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1126\/science.aay2767","volume":"369","author":"KK Payne","year":"2020","unstructured":"Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, et al. BTN3A1 governs antitumor responses by coordinating \u03b1\u03b2 and \u03b3\u03b4 T cells. Science. 2020;369:942\u20139.","journal-title":"Science"},{"key":"8924_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109359","volume":"36","author":"CE Cano","year":"2021","unstructured":"Cano CE, Pasero C, De Gassart A, Kerneur C, Gabriac M, Fullana M, et al. BTN2A1, an immune checkpoint targeting V\u03b39V\u03b42 T cell cytotoxicity against malignant cells. Cell Rep. 2021;36:109359.","journal-title":"Cell Rep"},{"key":"8924_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02302-0","volume":"24","author":"B Wang","year":"2025","unstructured":"Wang B, Wang Z, Zhou Z, Liu G, Jiang Z, Zheng M, et al. Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK\/mTOR pathway. Mol Cancer. 2025;24:97.","journal-title":"Mol Cancer"},{"key":"8924_CR29","doi-asserted-by":"publisher","first-page":"e1633235","DOI":"10.1080\/2162402X.2019.1633235","volume":"8","author":"S Verdura","year":"2019","unstructured":"Verdura S, Cuy\u00e0s E, Martin-Castillo B, Menendez JA. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. Oncoimmunology. 2019;8:e1633235.","journal-title":"Oncoimmunology"},{"key":"8924_CR30","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/cancers17152466","volume":"17","author":"A Rehman","year":"2025","unstructured":"Rehman A, Satyam SM, El-Tanani M, Prabhakar S, Kumari R, Shetty P, et al. Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer. Cancers (Basel). 2025;17:2466.","journal-title":"Cancers (Basel)"},{"key":"8924_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.4103\/jcrt.jcrt_2670_22","volume":"19","author":"Y Cao","year":"2023","unstructured":"Cao Y, Wo M, Xu C, Fei X, Jin J, Shan Z. An AMPK agonist suppresses the progress of colorectal cancer by regulating the polarization of TAM to M1 through inhibition of HIF-1\u03b1 and mTOR signal pathway. J Cancer Res Ther. 2023;19:1560\u20137.","journal-title":"J Cancer Res Ther"},{"key":"8924_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2019.02.014","volume":"450","author":"L Wang","year":"2019","unstructured":"Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497\/PELP1 axis. Cancer Lett. 2019;450:22\u201331.","journal-title":"Cancer Lett"},{"key":"8924_CR33","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.7150\/ijbs.104778","volume":"21","author":"Y Xie","year":"2025","unstructured":"Xie Y, Tian Y, Huang J, Deng W, Li X, Liu Y, et al. Metformin Alleviates Liver Metabolic Dysfunction in Polycystic Ovary Syndrome by Activating the Ethe1\/Keap1\/PINK1 Pathway. Int J Biol Sci. 2025;21:3505\u201326.","journal-title":"Int J Biol Sci"},{"key":"8924_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217694","volume":"622","author":"S Cai","year":"2025","unstructured":"Cai S, Deng Y, Zou Z, Tian W, Tang Z, Li J, et al. Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP\/PKG pathway activation. Cancer Lett. 2025;622:217694.","journal-title":"Cancer Lett"},{"key":"8924_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12929-025-01129-7","volume":"32","author":"Z Gu","year":"2025","unstructured":"Gu Z, Ye F, Luo H, Li X, Gong Y, Mao S, et al. Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. J Biomed Sci. 2025;32:36.","journal-title":"J Biomed Sci"},{"key":"8924_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07177-5","volume":"15","author":"K Yang","year":"2024","unstructured":"Yang K, Wang X, Zhang C, Liu D, Tao L. Metformin improves HPRT1-targeted purine metabolism and repairs NR4A1-mediated autophagic flux by modulating FoxO1 nucleocytoplasmic shuttling to treat postmenopausal osteoporosis. Cell Death Dis. 2024;15:795.","journal-title":"Cell Death Dis"},{"key":"8924_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4049\/jimmunol.1600948","volume":"198","author":"RCG de Bruin","year":"2017","unstructured":"de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebesty\u00e9n Z, et al. Prevention of V\u03b39V\u03b42 T Cell Activation by a V\u03b39V\u03b42 TCR Nanobody. J Immunol. 2017;198:308\u201317.","journal-title":"J Immunol"},{"key":"8924_CR38","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-22-3042","volume":"83","author":"X Huang","year":"2023","unstructured":"Huang X, Sun T, Wang J, Hong X, Chen H, Yan T, et al. Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer. Cancer Res. 2023;83:2358\u201371.","journal-title":"Cancer Res"},{"key":"8924_CR39","doi-asserted-by":"publisher","first-page":"e005719","DOI":"10.1136\/jitc-2022-005719","volume":"11","author":"V Finisguerra","year":"2023","unstructured":"Finisguerra V, Dvorakova T, Formenti M, Van Meerbeeck P, Mignion L, Gallez B, et al. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. J Immunother Cancer. 2023;11:e005719.","journal-title":"J Immunother Cancer"},{"key":"8924_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","volume":"78","author":"L Li","year":"2018","unstructured":"Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, et al. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. Cancer Res. 2018;78:1779\u201391.","journal-title":"Cancer Res"},{"key":"8924_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114345","volume":"151","author":"S Jafarzadeh","year":"2025","unstructured":"Jafarzadeh S, Nemati M, Zandvakili R, Jafarzadeh A. Modulation of M1 and M2 macrophage polarization by metformin: Implications for inflammatory diseases and malignant tumors. Int Immunopharmacol. 2025;151:114345.","journal-title":"Int Immunopharmacol"},{"key":"8924_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00262-007-0391-3","volume":"57","author":"F Bouet-Toussaint","year":"2008","unstructured":"Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pinti\u00e8re C, Daniel P, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother. 2008;57:531\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"8924_CR43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jnci\/djae021","volume":"116","author":"L O\u2019Connor","year":"2024","unstructured":"O\u2019Connor L, Bailey-Whyte M, Bhattacharya M, Butera G, Hardell KNL, Seidenberg AB, et al. Association of metformin use and cancer incidence: a systematic review and meta-analysis. J Natl Cancer Inst. 2024;116:518\u201329.","journal-title":"J Natl Cancer Inst"},{"key":"8924_CR44","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60:1586\u201393.","journal-title":"Diabetologia"},{"key":"8924_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021;42:77\u201396.","journal-title":"Endocr Rev"},{"key":"8924_CR46","doi-asserted-by":"publisher","first-page":"12892","DOI":"10.3390\/ijms232112892","volume":"23","author":"JL Goggi","year":"2022","unstructured":"Goggi JL, Hartimath SV, Khanapur S, Ramasamy B, Chin ZF, Cheng P, et al. Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with \u03b1PD-1 Therapy. Int J Mol Sci. 2022;23:12892.","journal-title":"Int J Mol Sci"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08924-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:02:43Z","timestamp":1786453363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08924-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8924"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08924-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study, conducted in compliance with the principles of the Declaration of Helsinki, was approved by the Ethics Committee of Henan Medical University (Approval No: [XYLL-20240393]). Written informed consent was obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"708"}}